Thyroid Dysfunction and Increased Risk of Developing Gestational Diabetes Mellitus by Lakshmi Sirisha, K
THYROID DYSFUNCTION AND INCREASED RISK OF DEVELOPING 
GESTATIONAL DIABETES MELLITUS 
 
A Dissertation Submitted to 
THE TAMILNADU Dr.M.G.R MEDICAL UNIVERSITY,  
 Chennai-600 032  
In partial fulfilment of the requirements for the award of the Degree of 
                                        MASTER OF PHARMACY 
IN 
PHARMACOLOGY 
 
                                                  Submitted by 
LAKSHMI SIRISHA K 
REGESTRATION No.261525903 
 
Under the Guidance of 
G.VENKATESH, M. Pharm., 
Department of Pharmacology 
 
 
 
PSG COLLEGE OF PHARMACY 
PEELAMEDU,  
COIMBATORE641 004 
  OCTOBER-2017 
 
  
 
Certificates 
 
      
                                                  G.VENKATESH., M. Pharm., 
Assistant Professor, Dept. of Pharmacology, 
PSG College of Pharmacy, 
Peelamedu, 
Coimbatore - 641 004 (T.N). 
 
 
 
CERTIFICATE 
 
 
This is to certify that the dissertation work entitled “Thyroid Dysfunction and Increased 
Risk of Developing Gestational Diabetes Mellitus” submitted by University Regd. 
No.261525903 is a bonafide work carried out by the candidate under my guidance and 
submitted to the Tamil Nadu Dr. M.G.R. Medical University, Chennai, in partial 
fulfilment for the Degree of Master of Pharmacy in Pharmacology at the Department of 
Pharmacology, PSG College of Pharmacy, Coimbatore, during the academic year      
2016-2017. 
 
 
 
 
 
 
                G.VENKATESH, M.Pharm.,              
                Assistant Professor& Guide. 
 
 
 
 
 
 
 
 
 
 
                                                 Dr. M. Ramanathan, M. Pharm., PhD.,                                                                                                                          
Principal & Head of the Department, 
PSG College of Pharmacy, 
Peelamedu, 
Coimbatore - 641 004 (T.N). 
 
 
 
 
CERTIFICATE 
 
 
This is to certify that the dissertation work entitled “Thyroid Dysfunction and Increased 
Risk of Developing Gestational Diabetes Mellitus” submitted by University Regd. 
No.261525903 is a bonafide work carried out by the candidate under the guidance of   
Mr.G.Venkatesh, M.Pharm., submitted to the Tamil Nadu Dr.M.G.R. Medical 
University, Chennai, in partial fulfilment for the Degree of Master of Pharmacy in 
Pharmacology at the Department of Pharmacology, PSG College of Pharmacy, 
Coimbatore, during the academic year 2016-2017. 
 
 
 
 
 Dr. M. Ramanathan, M. Pharm., PhD., 
  Principal & Head of the Department                                                                                          
 
 
 
 
 
 
  
 
 
DECLARATION 
 
 
I do hereby declare that the dissertation work entitled “Thyroid Dysfunction and 
Increased Risk of Developing Gestational Diabetes Mellitus” submitted to the Tamil 
Nadu Dr. M.G.R. Medical University, Chennai, in partial fulfilment for the Degree of 
Master of Pharmacy in Pharmacology, was done by me under the guidance of 
Mr.G.Venkatesh, M.Pharm., at the Department of Pharmacology, PSG College of 
Pharmacy, Coimbatore, during the academic year 2016-2017. 
 
 
 
 
 
 
 
University Reg. No: 261525903 
 EVALUATION CERTIFICATE 
 
 
This is to certify that the dissertation work entitled “Thyroid Dysfunction and Increased 
Risk of Developing Gestational Diabetes Mellitus” submitted by University Regd. 
No.261525903 to the Tamil Nadu Dr.M.G.R. Medical University, Chennai in partial 
fulfilment for the Degree of Master of Pharmacy in Pharmacology is a bonafide work 
carried out by the candidate at the Department of Pharmacology, PSG College of 
Pharmacy, Coimbatore and was evaluated by us during the year 2016-2017. 
 
 
 
Examination Center: PSG College of Pharmacy, Coimbatore. 
 
Date: 
 
 
 
 
 
 
 
 
Internal Examiner External Examiner 
  
 
 
Acknowledgment 
 
 
ACKNOWLEDGEMENT 
 
 I take this opportunity to render my profound sense of gratitude to my indebtedness and 
respectful regards to my teacher and guide Mr. G.Venkatesh, M. Pharm., Department of 
Pharmacology, for his valuable guidance, support and encouragement throughout the period 
of research. 
It’s my great honor to express whole hearted gratitude to beloved principal Dr. 
M.Ramanathan, M. Pharm., Ph.D., for providing me the necessary facilities to carry out the 
work successfully. 
I express my sincere thanks and heartfelt gratitude toDr. R.Senthilkumar, MD, MRCP., 
Associate professor& Head, Department of Endocrinology, for his valuable guidance and 
keen interest shown towards my work 
I owe my deepest gratitude to Dr. Seetha Panicker, MD, DG, DNB., Department of 
Obstetrics & Gynecology for her support and valuable ideas for my research work. 
I am thankful to Nurses and Patients without whose co-operation this dissertation would not 
have been possible. 
I heartily thank all my teachers and research scholars for their suggestions and constant 
support during the period of my study.           
I acknowledge with gratitude, the memorable company and co-operation extended by my 
friends for their timely help and support. 
My sincere thanks to Institutional Human Ethical Committee for approving my study. 
It’s my pleasure to thank all other Staff members, Lab Technicians, Library Staff and I 
submit my sincere thanks to ' PSG Sons’ and Charities for all the facilities that were 
provided to me at the institute enabling me to do the work of this magnitude. 
From the depth of my heart I would like to express my profound gratitude to my beloved 
parents and grandmother for their sacrifice and efforts beyond their limits. 
  
Dedicated 
To The Supreme Lord  
My beloved 
Grandmother 
& 
Parents 
ABBREVIATIONS 
 
ATA : American Thyroid Association 
ADA : American Diabetes Association 
ATA : Anti-Thyroid drugs 
AIDS : Acquired Immunodeficiency Syndrome 
ATMs : Adipose Tissue Macrophages 
c AMP : Cyclic Adenosine Monophosphate 
CI : Confidence Interval 
DIPSI : Diabetes In Pregnancy Study Group India 
ESCPG : Endocrine Society Clinical Practice Guidelines 
FT3 : Free Tri-iodothyronine 
FT4 : Free Thyroxine 
FAs : Fatty Acids 
GD : Grave’s Disease 
GDM : Gestational Diabetes Mellitus 
GLUT : Glucose Transporter 
 HCG : Human Chorionic Gonadotropin 
IHEC : Institutional Human Ethical Committee 
IRS : Insulin Receptor Substrate 
LT4 : Levothyroxine 
OGTT :     Oral Glucose Tolerance Test 
PCOD : Polycystic Ovarian Syndrome 
PTU : Propylthiouracil 
PKC : Protein kinase C 
SPSS :     Statistical Package for Social Sciences 
SOCS :     Suppressor of Cytokine Signaling 
SLE : Systemic Lupus Erythematosus 
TSH : Thyroid Stimulating Hormone 
TFTs : Thyroid Function Tests 
TBG : Thyroxine Binding Globulin  
T3 : Tri-iodothyronine 
TRL : Toll like Receptor 
 
 
 LIST OF FIGURES 
FIGURE 
NO. 
TITLE PAGE NO. 
1 Incidence of GDM in different age group patients 24 
2 Incidence of GDM in patients with different BMI 25 
3 
Incidence of GDM in patients with and without medical 
history 
27 
4 
Incidence of GDM in patients with and without History of 
PCOD 
28 
5 
Incidence of GDM in patients with and without History of 
Infertility 
29 
6 
comparison of mean TSH values between GDM and non 
GDM patients 
31 
7 
comparison of mean TSH values in overt hypothyroid 
group between GDM and non GDM patients 
32 
8 OGTT values of GDM patients in different groups 33 
9 Mean OGTT values of GDM patients in different group 34 
10 Mean OGTT values Euthyroid vs overt hypothyroid group 35 
11 Incidence of GDM in different age group patients 37 
 
 
 
 
 
LIST OF TABLES 
 
TABLE 
NO. 
TITLE PAGE NO. 
1 
TSH cut off values according to American thyroid 
association guidelines 
20 
2 TSH reference values in different trimesters. 20 
3 Demographic data of the study population 22 
4 
Comparison of the Demographic Factors across the study 
population 
23 
5 
Comparison of the clinical characteristics across the 
study population 
26 
6 
Comparison of Thyrotropin (TSH) values in early 
pregnancy between GDM and non-GDM pregnant 
women. 
30 
7 Comparison of OGTT values in GDM patients 33 
8 
Group wise Correlation of clinical characteristics with 
GDM using Pearson correlation analysis 
36 
9 GDM risk analysis using Odds ratio 38 
 
 
 
 
 
 
 
 
 
  
 
Contents 
 
LIST OF CONTENTS 
 
SL.NO. CONTENTS PAGE NO. 
1 Introduction 1 
2 Literature Review 10 
3 Aim and Objective 15 
4 Plan of Study 16 
5 Materials and Methods 17 
6 Results 22 
7 Discussions 39 
8 Summary and conclusion 44 
9 Future Outlook 46 
10 Reference 47 
11 Annexures - 
 
 
 
 
 
 
 
 
Chapter 1 
 
 
 
 
 
 
 
 
 Introduction  
 Introduction 
 
Department of Pharmacology, PSGCOP Page1 
 
1. INTRODUCTION 
 
Thyroid disorders are among the common endocrine problems in pregnant women. Thyroid 
disorders occur when thyroid gland releases more (over active) or less (underactive) thyroid 
hormones. Thyroid hormone production is regulated by thyroid-stimulating hormone (TSH), 
which is made by the pituitary gland in the brain (Sahu et al., 2010).Thyroid disease affects 
2–3% of pregnant women and is associated with adverse pregnancy outcomes. (Abalovich et 
al., 2007; Fitzpatrick and Russell, 2010; Van Den Boogaard et al., 2011). 
 
HYPERTHYROIDISM IN PREGNANCY 
When thyroid gland releases more (overactive) thyroid hormones that condition is called 
Hyperthyroidism. The prevalence of clinical Hyperthyroidism is found in 0.1–0.4% of 
pregnant women. 
Types 
Overt hyperthyroidism is seen in nearly 0.002% of pregnancy characterized by a reduced 
TSH and an increased FT3/FT4 (Brent et al., 2007).Subclinical hyperthyroidism is seen in 
1.7% of pregnancy and is characterized by a suppressed serum TSH and normal FT4(Brent et 
al., 2007) 
Causes 
Most common cause is Graves’ disease. (Bahn et al., 2011)other causes of hyperthyroidism in 
pregnancy include subacute thyroiditis, toxic multinodular goiter, toxic thyroid adenoma and 
excessive LT4 intake.(Patil-Sisodia et al.,2010;Mestman et al.,2010) 
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Complications 
If left untreated hyperthyroidism significantly increases the risk of pregnancy and poor fetal 
outcomes, which includes 
 Miscarriage 
 Preeclampsia 
 preterm birth 
 Placental abruption  
 Fetal hyperthyroidism (Zimmerman, 1999; Earl et al., 2010). 
Treatment 
According to the Endocrine Society Clinical Practice Guideline (ESCPG) and the American 
Thyroid Association (ATA), the treatment of choice is with two Anti thyroid drugs (ATDs), 
MMI and propylthiouracil (PTU), both cross the placenta and hence are used to treat 
hyperthyroidism. The goal of ATD therapy in pregnant women with hyperthyroidism is to 
maintain maternal serum FT4 at or just above the upper limit of normal for pregnancy using 
the smallest ATD dose possible.  Propylthiouracil (PTU). (Abalovich et al., 2007; Stagnaro-
Green et al., 2011). 
 
HYPOTHYROIDISM DURING PREGNANCY 
When thyroid gland releases more less (underactive) thyroid hormones that condition is called 
Hypothyroidism. The prevalence of clinical hypothyroidism is 0.3–0.5% in pregnant women 
(Abalovich et al., 2007). 
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Types 
Subclinical hypothyroidism, which is characterized by an elevated serum TSH with normal 
free thyroxine (FT4) and is observed in 3%–5% of women in pregnancy. (Reid et al., 2013). 
Overt hypothyroidism, characterized by an elevated serum TSH and abnormal FT4 is 
observed in 0.3%–0.5% of women in pregnancy (Reid et al., 2013). 
Causes 
Hypothyroidism in women of reproductive age is most commonly caused by autoimmune 
thyroiditis, Hashimoto’s disease (Abalovich et al., 2007). Other causes include prior 
radioactive iodine and/or surgical ablation of Graves’ disease (GD) (Neale et al.,2004;Burrow 
et al.,2004)surgical removal of the thyroid because of multinodular goiter or thyroid cancer, 
overtreatment of hyperthyroidism with thionamides, medications that alter the absorption or 
metabolism of LT4, and central defects that inhibit the hypothalamic-pituitary-thyroid axis. 
The fetal thyroid gland starts producing small amounts of thyroid hormone at approximately 
10 weeks’ gestation, until production plateaus at approximately 35 weeks. (Glinoer et al., 
1990; Nayer et al., 1990) 
Thus, particularly in the first trimester of pregnancy, the fetus depends entirely on thyroid 
hormone from the mother.  
Complications 
Maternal hypothyroidism can have devastating consequences if left untreated.  
It is associated with: 
 Spontaneous abortion (Abalovich et al., 2002; Gutierrez et al., 2002) 
 Fetal death (Allan et al., 2000; Palomaki et al., 2000) 
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 Preterm delivery (Stagnaro-Green et al., 2009; Allan et al., 2000; Palomaki et al., 
2000) 
 Pregnancy induced hypertension (Leung et al., 1993. Millar et al.,1993) 
 Gestational diabetes (Stagnaro-Green et al., 2009) 
 Anemia, 
 Postpartum hemorrhage. (Davis et al., 1998; Leveno et al., 1998) 
 Placental abruption and preterm labor (Casey et al., 2005; Dashe et al., 2005) 
 Preeclampsia (Ashoor et al., 2010; Rotas et al., 2010) 
 Cesarean section (Cohen et al., 2010; Wiznitzer et al., 2010) 
 Early embryo loss (De Vivo et al., 2010; Mancuso et al., 2010) 
 Placental abruption  
 Preterm labor (Casey et al., 2005; Dashe et al., 2005) 
 Low birth weight 
 Fetal distress 
 Impaired neuropsychological development. 
 Lower intelligence scores. (Haddow et al., 1999; Li et al., 2010; van den Boogaard et 
al., 2011). 
Treatment  
Treatment with levothyroxine is recommended and considered safe in pregnancy. (Abalovich 
et al., 2007).The goal of treatment is to maintain TSH within trimester-specific reference 
ranges: 
0.1 to 2.5 mIU/L in the first trimester, 
0.2 to 3.0 mIU/L in the second trimester, and 
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0.3 to 3.0 mIU/L in the third trimester. (Stagnaro-Green et al., 2011; Abalovich et al., 2011) 
Thyroid function should be normalized as rapidly as possible after conception. TFTs 
ismeasured within 30 to 40 days of the first positive pregnancy test, and then every 4 to 6 
weeks throughout pregnancy. 
 
Physiological changes of Thyroid gland in pregnancy 
Data from human and animal studies suggest that pregnancy alters normal thyroid function 
(Weetman et al., 2010). Thyroid physiology changes significantly during pregnancy. (Glinoer 
et al., 1997).  During pregnancy, the thyroid gland increases in size by 10% in iodine replete 
countries, but by 20% to 40% in areas of iodine deficiency (ADA et al., 2014).  The metabolic 
changes include: 
1. Increase in Iodine Renal Clearance 
During pregnancy, there is an enhanced urinary loss of iodine owing to an increased 
glomerular filtration rate, leading to iodine deficiency and maternal goiter (Banerjee et al., 
2011). 
2. The impact of Human Chorionic Gonadotrophin (HCG) on the Thyrotrope Receptor 
Decrease in the level of thyroid-stimulating hormone (TSH) with an increase in pregnancy 
related hormone concentration- Human Chorionic Gonadotropin (Galofre et al., 2009). 
3. An increase in serum Thyroxine-Binding Globulin (TBG) 
There is an increase in thyroxine-binding globulin (TBG) because of elevated oestrogen a 
protein that transports thyroid hormone in the blood (Galofre et al., 2009).   
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4. Inner-ring Deiodination of Triiodothyronine (T3) and Thyroxine (T4) by the placenta 
Placenta produces the enzyme type 3 deiodinase, which increases the peripheral metabolism 
of thyroid hormones and regulates the trans-placental transport of thyroid hormone and iodide 
(Landers et al., 2009). 
 
A variety of endocrine disorders complicate pregnancy. Diabetes is the most prevalent and 
has been seen increasing prevalence of Diabetes in general and in young people in particular, 
which has led to increase in the number of Pregnancy with diabetes. 
 
Gestational Diabetes Mellitus (GDM) 
GDM is defined as glucose intolerance of varying degree with onset or first recognition 
during pregnancy. The prevalence of GDM in India varied from 3.8 to 21% in different parts 
of the country, depending on the geographical locations and diagnostic methods used. GDM 
has been found to be more prevalent in urban areas than in rural areas.  The importance of 
GDM is that two generations are at risk of developing diabetes in the future. Women with a 
history of GDM are at increased risk of developing predominately type 2 diabetes and also 
their children. (Yogev et al., 2004) 
 
Pathophysiology of GDM  
GDM is closely associated with Diabetes mellitus type II, due to similarities in their many key 
pathophysiologic characteristics most importantly, insulin resistance. During pregnancy, 
woman develops insulin resistance, mainly due to hormone production. Some of these 
hormones are estrogen, cortisol, and human placental lactogen. These hormones can have a 
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blocking effect on insulin. This is called contra-insulin effect, which usually begins about 20 
to 24 weeks in the pregnancy. As the placenta grows, more of these hormones are produced, 
and the risk of insulin resistance becomes greater. Normally, the pancreas is able to make 
additional insulin to overcome insulin resistance, but when the production of insulin is not 
enough to overcome the effect of the placental hormones, it results in gestational diabetes. 
(Poulakos et al., 2014). 
 
Risk factors for Gestational Diabetes Mellitus 
Although any woman can develop GDM during pregnancy, some of the factors that may 
increase the risk include the following (Chen P et al., 2015; Alfadhli et al., 2015) 
 Overweight or obesity 
 Family history of diabetes 
 Having given birth previously to an infant weighing greater than 9 pounds 
 Age (women age >25 are at a greater risk for developing gestational diabetes 
than younger women) 
 
 Prediabetes, also known as impaired glucose tolerance 
 
Adverse outcomes associated with GDM 
Maternal (Wei et al., 2015; Alfadhli et al., 2015) 
 Preeclampsia 
 Women with a history of GDM have approximately a 30% likelihood of 
developing DM type 2 within 10 years 
 Gestational hypertension 
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 Cesarean delivery 
 Women with a history of GDM have up to a 60% likelihood of developing 
GDM in a future pregnancy 
Fetal (Wei et al., 2015; Alfadhli et al., 2015) 
 Shoulder dystocia/birth trauma 
 Macrosomia 
 Birth defects 
 Hyperbilirubinemia 
 Hypoglycemia 
 
Treatment for GDM 
First-line treatment for GDM is medical nutritional therapy, moderate exercise has been used 
in the management of GDM (ADA 2014).Pharmacotherapy is implemented when medical 
nutritional therapy and lifestyle measures fail. Insulin is the mainstay of pharmacotherapy. 
(ADA 2014).Insulin regimens can include intermediate and short acting insulin such as the 
regular recombinant insulin analogs aspart, lispro. Historically, insulin has been the drug of 
choice for the management of women with GDM. 
Oral hypoglycemic agents such as glyburide (second generation sulfonylurea) and metformin 
(biguanide) are attractive alternatives to insulin due to lower cost, ease of administration, and 
better patient adherence. (Ryu et al., 2014). 
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Parameters 
Thyroid function assessment 
At the first antenatal visit (gestational age: 9–13 weeks), maternal serum samples were 
collected in 10 ml vacutainer tubes, centrifuged, and stored in aliquots at –80°C until assayed. 
Quantitative analyses of thyroid hormones [TSH] were performed using chemiluminescent 
microparticle immunoassays. 
 
Oral Glucose Tolerance Test (OGTT) 
The women were screened for Gestational Diabetes Mellitus (GDM) at 24–28 weeks and 
classified at that time as having GDM in the index pregnancy if any abnormal plasma glucose 
values were obtained during the 2 hours, 75g OGTT according to the Diabetes in Pregnancy 
Study Group India (DIPSI) diagnostic criteria. 
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2. LITERATURE REVIEW 
 
Thyroid disorders are one of the most common endocrine disorders in pregnancy. Thyroid 
disorders are known to be associated with abnormal maternal and fetal outcomes and are often 
overlooked in pregnant women because of nonspecific symptoms and hypermetabolic state of 
pregnancy. 
 
Krajewski et al., 2011 studied thyroid disorders in pregnancy and suggests that Normal 
thyroid function is essential in pregnancy to avoid complications in gestation and to ensure 
delivery, to the best extent possible, of a healthy baby. Women with hypothyroidism and (or) 
thyroid antibodies are at increased risk of miscarriage. Low thyroid hormone levels during 
pregnancy can have detrimental effects on the development of the fetal central nervous system 
and predispose to preterm delivery and spontaneous pregnancy loss. 
 
Negro et al., 2014 examined the peer-reviewed literature on hypothyroidism, hyperthyroidism 
and thyroid autoimmunity in pregnancy. Results suggests that overt hyperthyroidism and 
hypothyroidism are responsible for adverse obstetric and neonatal events. Thus concluded that 
overt hyperthyroidism and hypothyroidism need to be promptly treated and subclinical 
hypothyroidism also requires substitutive treatment. 
 
Vissenberg et al., 2012 conducted a systematic review which provides a comprehensive 
overview on the available treatment interventions on thyroid disorders before conception and 
in early pregnancy. Results suggests that for hyperthyroidism, methimazole and PTU are 
 Literature Review 
 
Department of Pharmacology, PSGCOP Page 11 
 
effective in preventing pregnancy complications. For clinical hypothyroidism, treatment with 
levothyroxine is recommended. For subclinical hypothyroidism and thyroid autoimmunity, 
evidence is insufficient to recommend treatment with levothyroxine. 
 
Jahagirdar et al., 2012 evaluated Thyroid hormone role in regulating brain glucose 
metabolism and potentially modulating hippocampal cognitive processes. This review 
discusses evidence for mechanistic links between TH, insulin, cognitive function and brain 
glucose metabolism and reaches the conclusion that TH may modulate memory processes, 
likely at least in part by modulation of central insulin signaling and glucose metabolism. 
 
Karakosta et al., 2012 studied the association of thyroid function and autoimmunity in early 
pregnancy with adverse pregnancy and birth outcomes. The study used data from the 
prospective mother-child cohort “Rhea” study in Crete, Greece. A total of 1170 women with 
singleton pregnancies participated in this analysis.  Maternal serum samples in the first 
trimester of pregnancy were tested for thyroid hormones (TSH, freeT4 and free T3) and 
thyroid antibodies (thyroid peroxidase antibody and thyroglobulin antibody). Outcomes 
included gestational diabetes, gestational hypertension/preeclampsia, cesarean section, 
preterm delivery, low birth weight. The combination of high TSH and thyroid autoimmunity 
in early pregnancy was associated with a 4-fold increased risk for gestational diabetes and a 3-
fold increased risk for low birth weight neonates. 
 
Stohl et al., 2013 have evaluated if there is any connection between thyroid disease and 
gestational diabetes. They used retrospective data of all women with clinical thyroid disease 
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delivering at Johns Hopkins Hospital from January 2005 to December 2008. Clinical 
Parameters were abstracted and appropriate statistical tests were performed. Results states that 
GDM occurred in 12.3% of women in the study cohort. In hypothyroid women, 14.3% 
developed GDM compared to 5.8% of hyperthyroid women. If larger studies confirm the 
trends observed in this study, consideration should be given to including women with known 
thyroid disease in the subset of women who should be offered screening for diabetes early in 
pregnancy and appropriate clinical surveillance. 
 
Shuai Yang et al., 2016 have evaluated the correlations between different thyroid hormone 
levels in early pregnancy and the incidence of gestational diabetes mellitus. The study 
comprised 27,513motherswho provided early pregnancy serum samples for analyses of 
thyroid function. GDM was diagnosed using a 2 h, 75 g oral glucose tolerance test between 
24-28weeks of gestation. The incidence of GDM in pregnant women tended to increase with 
age (5.83%, 10.18%, 14.95%, 22.40%, P<0.0001), increasing pre-pregnancy body mass index 
(BMI) (P<0.0001), a family history of diabetes (21.09% vs. 12.92%, P<0.0001).It was 
observed that the level of free T4 (FT4) in early pregnancy in GDM women was lower than 
that in non GDM women (P <0.0001). Increasing FT4 levels were associated with a protective 
effect against GDM thereby concluding that low thyroid hormone levels in early pregnancy 
are a risk factor for GDM incidence. 
 
Tudela et al., 2012 have evaluated if there is any relationship between subclinical thyroid 
disease and gestational diabetes between November 2000 and April 2003, serum thyrotropin 
screening was performed on all women who presented for prenatal care. Women with an 
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elevated serum thyrotropin but a normal serum free thyroxine were designated to have 
subclinical hypothyroidism and those with a low thyrotropin and a normal serum free 
thyroxine level were designated to have subclinical hyperthyroidism. Euthyroid women had 
both normal thyrotropin and normal serum free thyroxine values. The incidence of gestational 
diabetes was compared among these three groups. Of the 24,883 women included in the 
study, 23,771 (95.5%) were Euthyroid, 584 (2.3%) had subclinical hyperthyroidism and 528 
(2%) had subclinical hypothyroidism. The risk of developing gestational diabetes increased 
with thyrotropin level. There by supporting a relationship between subclinical hypothyroidism 
and diabetes diagnosed during pregnancy. 
 
Das Bishnu Prasad et al., 2015 have studied the relationship between gestational diabetes 
mellitus with hypothyroidism in pregnancy between June 2014 and May 2015.They had 2 
groups of patients 100 in each group, Euthyroid group (control) and hypothyroid (study) 
group. Grouping was done based on the serum thyrotropin (TSH) levels, normal thyrotropin 
values were taken as 0.2 to 3mIU/L as per American Thyroid Association guidelines. Patients 
from both the groups were subjected to oral glucose tolerance test with 75gm oral glucose 
according to DIPSI guidelines. The incidence of gestational diabetes mellitus was compared 
between the study and the control group Gestational diabetes was more in the hypothyroid 
group (8%) than in the control group (1%), (P= 0.0349).The risk of developing gestational 
diabetes increases with hypothyroidism.  This supports a relationship between hypothyroidism 
and diabetes, diagnosed during pregnancy. 
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Li-Li Gong et al., 2015 conducted a meta-analysis to investigate whether hypothyroidism in 
Pregnancy is associated with gestational diabetes risk. They searched the published literature 
from PubMed and EMBASE. Pooled odds ratio (OR) and 95% confidence interval (CI) were 
calculated using a fixed- or random-effects model. Seven articles described the relationship 
between hypothyroidism and risk of gestational diabetes. This meta-analysis revealed that 
overt hypothyroidism was associated with an increased risk of gestational diabetes (OR 1.892, 
95% CI 1.679e2.132, p < 0.001). The relative risk of gestational diabetes was also increased 
in subclinical hypothyroidism, with the OR of 1.558 (95% CI 1.292e1.877, p < 0.001).There 
was no evidence of significant association between hypothyroxinemia and risk of gestational 
diabetes (OR 1.394, 95% CI 0.753e2.580, p ¼ 0.291). The OR for all of the hypothyroidism 
was 1.749 (95%) CI 1.586e1.928, p < 0.001), and an association was found. 
 
Chapter 3  
 
 
 
 
 
 
 
 
Aim & Objective  
 Aim and Objective 
 
Department of Pharmacology, PSGCOP Page 15 
 
 
 
3. AIM AND OBJECTIVE 
 
 
 To investigate the association between thyroid dysfunction in pregnancy and risk of 
developing gestational diabetes mellitus. 
 To identify the other risk factors for developing gestational diabetes mellitus. 
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4. PLAN OF STUDY 
 
PHASE- I (3 months): 
 Preliminary literature survey 
 Protocol preparation 
PHASE – II (6 months): 
 Obtaining approval from Institutional Human Ethical Committee 
 Allocation of cases 
 Data collection 
PHASE – III (3 months): 
 Data interpretation 
 Statistics 
 Results 
 Discussion  
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5. MATERIALS AND METHODS 
 
STUDY TYPE 
Observational  
STUDY DESIGN 
Prospective 
STUDY CENTER 
Department of Endocrinology, Obstetrics & Gynaecology, PSG IMS&R 
Coimbatore. It is a multi-speciality 900 bedded tertiary care hospital located in the southern 
part of Tamilnadu. 
STUDY POPULATION 
Pregnant Women 
SAMPLE SIZE 
204 patients 
STUDY DURATION 
1year 
STUDY PERIOD 
November 2016 to July2017 
INCLUSIVE CRITERIA 
 Pregnant women with Age > 18 yrs 
EXCLUSIVE CRITERIA 
 Cases with Diabetes mellitus (Type -1  or Type -2) diagnosed prior to pregnancy 
 Pregnancy with more than one foetus 
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 Chronic medical conditions such as HIV/AIDS, kidney disease, SLE and Autoimmune 
diseases 
STUDY TOOLS: 
Patient Data Collection Form 
STUDY APPROVAL: 
The approval for the study was obtained from Institutional Human Ethical Committee 
(IHEC), PSGIMSR. Project No: 16/438. 
 
GROUPING
 
 
STUDY PROCEDURE: 
 The study protocol was prepared and submitted to the Institutional Human Ethical 
Committee (IHEC) for approval.  
 The protocol was approved by IHEC.  
 This was then informed and the permit was obtained from the Heads of Departments, 
Obstetrics&Gynecologyand Endocrinology, PSG Hospitals, Coimbatore. 
Grouping
Group 1
Euthyroid
Group2
Subclinical 
hypothyroid
Group 3
Overt hypothyroid
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 The study was commenced in the outpatient Departments of Obstetrics&Gynecology 
and Endocrinology, PSG Hospitals, Coimbatore.  
 All the pregnant women above18 years, present for antenatal care, were explained 
about the study protocol in the language understandable to them (English, Tamil). 
 Written informed consent was obtained from thepatients who agreed and were 
enrolled in the study.  
 Demographic details such as age, BMI,occupation, contact information and all the 
data concerning their medical history was obtained.  
 Study participants were screened for Serum Thyrotropin levels (TSH, FT4) during 
their first trimester (9 -13 weeks)based on which they were grouped (Table -1),cut off 
values were obtained from ‘AMERICAN THYROID ASSOCIATION’2017 (Table -
2)and were followed up until their second trimester 
 Between (24-28weeks) they were subjected to oral glucose tolerance test according to 
DIPSI guidelines for GDM diagnosis. 
 
DIAGNOSIS OF GDM 
Diabetes in pregnancy study group India (DIPSI) diagnostic criteria,diagnosed based on the 2 
– hour 75gm oral glucose tolerance test (OGTT) with a threshold plasma glucose 
concentration greater than 140 mg/ dl at 2 hour, performed in fasting /non –fasting state 
irrespective of the last meal timing. 
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Table 1. TSH cut off values according to American thyroid association guidelines 
GROUPS TSH VALUES PATIENT CONDITION 
GROUP -1 0.1-2.5mU/L EUTHYROID 
GROUP-2 >2.5mU/L SUBCLINICAL HYPOTHYROID 
GROUP-3 >10mU/L OVERT HYPOTHYROID 
 
Table 2. TSH reference values in different trimesters. 
 
 
 
 
 
 
STATISTICAL ANALYSIS 
Data were analyzed using the Statistical package for social sciences (IBM SPSS, version 19). 
Incidence of GDM with the demographic factors and clinical characteristicswere assessed by 
ANOVA andstudent’s t-test. Group wise correlation between the clinical characteristics and 
GDM were assessed by Pearson’s x2 test. GDM risk analysis between the groups were 
assessed by odds ratio (OR), and exact 95% confidence intervals (CI). P values <0.5 were 
considered as statistically significant. 
 
 
 
 
GESTATIONAL AGE TSH REFERENCE VALUES 
FIRST TRIMESTER 0.1 – 2.5mU/L 
SECOND TRIMESTER 0.2 – 3.0mU/L 
THIRD TRIMESTER 0.3 – 3.0mU/L 
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STUDY PROCEDURE (flow chart) 
 
 
 
RResult
Statisticstics
Data interpretation
GDM Diagnosis b/w 24-28 weeks by OGTT according to 
DIPSI Guidelines
Follow up until II trimester
Subclinical hypothyroid
Thyroid function assessment (TSH) b/w 9-13 
weeks
Demographic data &medical history was 
Protocol was explained and written consent was obtained
Pregnant women above 18 yrs. of age were identified
Euthyroid 
 
Overt hypothyroid 
 
Chapter 6  
 
 
 
 
 
 
 
 
Results 
 Results 
 
Department of Pharmacology, PSGCOP Page22 
 
6. RESULTS 
 
 
Table 3. Demographic data of the study population. 
 
DEMOGRAPHICS 
EUTHYROID 
 
SUBCLINICAL 
HYPO- 
THYROID 
 
OVERT HYPO- 
THYROID 
 
Total Patients n (%) 100(49.02) 78(38.23) 26(12.75) 
 
 
 
 
Age 
± SD 25.6±3.9 26.5± 4.4 25.3±3.5 
< 25 n (%) 43(43) 27(34.6) 11(42.3) 
25-29 n (%) 39(39) 29(37.1) 10(38.46) 
30-34 n (%) 15(15) 17(21.7) 5(19.23) 
≥35 n (%) 3(3) 5(6.14) 0 
 
 
 
 
BMI  pre-
pregnancy(kg/
m2) 
±SD 24.4± 4.1 25.1± 4.3 26.4± 3.2 
Underweight  
n (%) 
9(9) 2(2.56) - 
Normal 
weight n (%) 
40(40) 29(37.94) 6(23.07) 
Overweight 
n (%) 
 
34(34) 34(43.5) 14(53.84) 
Obese n (%) 17(17) 13(16.66) 6(23.07) 
 
Occupation 
n (%) 
working 14(14) 16(20.5) 7(26.9) 
House wife 86(86) 62(79.48) 19(73.7) 
Family History of Diabetes  
n (%) 
18(18) 25(32.05) 8(30.76) 
History of GDM  
n (%) 
3(3) 4(5.12) 1(3.86) 
History of PCOD  
n (%) 
6(6) 4(5.12) 2(7.69) 
History of Thyroid 
n (%) 
1(1) 17(21.79) 4(15.38) 
History of Infertility 
n (%) 
3(3) 3(3.84) 4(15.38) 
n- Number of patients 
(%) – Percentage 
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Table 4. Comparison of the Demographic Factors across the study population 
 
Demographic Factors Number of 
Patients (%) 
No. of GDM 
patients (%) 
P values 
 
 
Age 
< 25 81 (39.7%) 10(12.34%) 
 
 
 
 
0.2053 
 
 
 
25-29 78(38.2%) 12(15.38%) 
30-34 37(18.1%) 6(16.21%) 
≥35 8(3.92%) 3(37.5%) 
 
BMI 
pre-pregnancy 
(kg/m2) 
Underweight 11(5.39%) 1 (9.09%) 
 
 
 
 
0.0738 
 
Normal weight 75 (36.76%) 9 (12%) 
Overweight 82 (40.19%) 14(17.07%) 
Obesity 36 (17.64%) 6 (16.66%) 
Occupation 
working 37 (18.13%) 6(1.62%) 
 
 
0.2877 
 House wife 167(81.86%) 24 (14.3%) 
 
Data was analyzed using ANOVA (analysis of variance) and Student’s t test, P values <0.5 
were considered as statistically significant. 
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Fig. No. 1: Incidence of GDM in different age group patients   
 
 
 
 
 
 
 
39.75%of study population were in the age group <25yrs out of which 12.34% had developed 
GDM. 38.2% of the study population were between the age group 25 to 29 out of 
which15.38% had developed GDM.18.1% of the study population were between the age 
group 30 to 34 out of which 16.21% developed GDM. 3.92% of the study population were of 
the age ≥35 out of which 37.5%developed GDM. 
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Fig. No. 2: Incidence of GDM in patients with different BMI 
 
 
 
 
 
 
 
 
5.39% of the study population who were underweight had 9.09% incidence of GDM. 36.9% 
of the study population who were normal weight had 12% incidence of GDM.40.19%of the 
study population who were overweight had 17.07% incidence of GDM. 17.64% of the study 
population who were obese had 16.66% incidence of GDM. 
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Table 5. Comparison of the clinical characteristics across the study population. 
 
 
Clinical 
characteristics 
Total Number of 
Patients (%) 
No. of GDM Patients 
(%) 
P values 
With Without With Without 
Family history of 
Diabetes 
51(24.5%) 153(75%) 9(17.6%) 21(13.7%) 0.257 
History of GDM 8(3.9%) 196(96%) 2(25%) 28(14.2%) 0.280 
History of PCOD 12(5.8%) 192(94.1%) 5(41.6%) 25(13%) 0.037* 
History of Thyroid 22(10.7%) 182(89.2%) 4(18.1%) 26(14.2%) 0.589 
History of Infertility 10(4.9%) 194(95%) 4 (40%) 26(13.4%) 0.003*** 
 
Data was analyzed using Student’s t test, P values <0.5 were considered as statistically 
significant. 
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Fig. No. 3: Incidence ofGDM in patients with and without medical history  
 
 
 
 
 
There was a slight increase in the incidence of GDM in patients who are having a family 
history of diabetes when compared with those without family history of diabetes (17.67% 
vs.13.7%), in patients with history of thyroid than those without history of thyroid (18.1% vs. 
14.2%), in patients with history of GDM when compared with those without (25% vs. 
14.2%).There was significant increase in the incidence of GDM in patients who are having a 
history of PCOD when compared with those without history of PCOD (41.6% vs. 13%) and 
in patients with history of infertility than those without history of infertility (40% vs. 13.4%) 
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Fig. No. 4: Incidence of GDM in patients with and without History of PCOD 
 
 
 
Data are expressed as mean ±SD. Statistical analysis was carried out using Student’s t test.* 
denotes statistical significance of pregnant women with a family history of PCOD having 
higher incidence of GDM than those without family history of PCOD (41.6% vs. 13%, p 
=0.037, P <.05). 
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Fig. No. 5: Incidence of GDM in patients with and without History of Infertility 
 
 
 
 
Data are expressed as mean ±SD. Statistical analysis was carried out using Student’s t test. 
*** denotes statistical significance of Pregnant women with a family history of infertility 
having much higher incidence of GDM than those without family history of infertility (40% 
vs. 13.4%, p =0.001, P <.001). 
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Table 6. Comparison of Thyrotropin (TSH) values in early pregnancy between GDM 
and non-GDM pregnant women 
 
Patients 
TSH values((mU/liter) 
 
P value Non-GDM GDM 
Total Patients 3.662  (n=174) 7.299 (n=30) 0.0358* 
Euthyroid 1.485 (n=89) 1.431 (n=11) 0.8022 
Subclinical 
Hypothyroid 
4.961  (n=32) 4.611 (n=14) 0.5584 
Overt Hypothyroid 11.18 (n=19) 24.16 (n=5) 0.0145* 
 
Data was analyzed using Student’s t test, P values <0.5 were considered as statistically  
Significant. 
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Fig. No. 6: comparison of mean TSH values between GDM and non GDM patients. 
 
 
 
 
 
 
In Euthyroid group mean TSH values slightly decreased in GDM patients when compared 
with and non GDM patients (1.431mU/liter vs.1.485mU/liter). In subclinical hypothyroid 
group mean TSH values slightly decreased in GDM patients when compared to non GDM 
patients (4.611mU/liter vs. 4.961mU/liter). In Overt hypothyroid group mean TSH values 
increased in GDM patients when compared with non GDM patients (24.16mU/liter vs. 
11.18mU/liter). 
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Fig. No. 7: comparison of mean TSH values inovert hypothyroid group between GDM 
and non GDM patients 
 
 
 
 
Data are expressed as mean ±SD. Statistical analysis was carried out using Student’s t test. * 
denotes statistical significance ofmean serum TSH in overt hypothyroid patients with GDM 
when compared with non GDM patients within the same group (24.6mU/liter vs. 
11.18mU/liter, p=0.014). 
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Table 7. Comparison of OGTT values in GDM patients. 
 
 
OGTT Values Euthyroid 
Subclinical 
Hypothyroid 
Overt Hypothyroid 
≥140 
 
144.8(n=11) 
 
149.6(n=14) 169.2(n=5) 
P value 0.0617 < 0.001*** 
 
 
Fig. No. 8: Mean OGTT values of GDM patients in different group  
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Fig. No. 9: OGTT values of GDM patients in different groups 
 
 
 
 
The OGTT values of  GDM patients are shown in the above graph.   OGTT values of 
euthyroid patients are in the range between 140mg/dl to 152mg/dl, in subclinically 
hypothyroid patients the values are in between 140mg/dl to 160mg/dl and in overthypothyroid 
patients the values ranging between 150mg/dl to 185 
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Fig. No.10: Mean OGTT values Euthyroid vs overt hypothyroid group 
 
 
 
 
Data are expressed as mean ±SD. Statistical analysis was carried out using Student’s t test. 
*** denotes statistical significance of mean OGTT values inovert hypothyroid group when 
compared with Euthyroid group (144.8mg/dl vs. 16.2 mg/dl, P< 0.001) 
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Table 8.  Group wise Correlation of clinical characteristics with GDM using Pearson 
correlation analysis. 
Clinical 
characteristics 
Correlation values 
Euthyroid 
Subclinical 
hypothyroid 
Overt Hypothyroid 
Age 0.123 0.0042* 0.9378 
BMI 0.864 0.3118 0.2509 
Occupation 0.134 0.5303 0.7115 
Family History of 
Diabetes 
0.002 0.050 0.150 
History of GDM 0.062 0.043 0.410* 
History of PCOD 0.180 0.043 0.703** 
History of Thyroid -0.035 0.014 0.015 
History of Infertility 0.313** 0.080 0.592** 
 
Correlation analysis was performed using Pearson’s x2 test. 
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Fig. No. 11: Group wise Correlation of clinical characteristics with GDM using Pearson 
correlation analysis. 
 
 
 
 
In Euthyroid group there is a positive correlation between history of infertility and GDM 
(0.313).In subclinical hypothyroid group there is a positive correlation between age and GDM 
(0.004).In overt Hypothyroid group there is a positive correlation between history of GDM 
and GDM (0.410), history of PCOD and GDM (0.703), history of infertility and GDM 
(0.592). 
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Table 9. GDM risk analysis using Odds ratio 
 
Odd Ratios Value 
95% Confidence Interval 
Lower Upper 
Odds Ratio for group  
(Euthyroid / subclinical) 
1.770 0.755 4.151 
Odds Ratio for group  
(Euthyroid / overt hypothyroid) 
1.926 0.604 6.140 
 
 
 
Subclinical hypothyroid group has 1.7 times more risk for developing gestational diabetes 
mellitus when compared with Euthyroid group. Overt hypothyroid group has 1.9 times more 
risk for developing gestational diabetes mellitus when compared with Euthyroid group. 
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7. DISCUSSION 
The studies exploring the association between thyroid dysfunction and gestational diabetes are 
comparatively less in the Indian population, the incidence of gestational diabetes mellitus 
(GDM) in pregnant women with thyroid disorders is less clear, so the aim of this 
observational, prospective study was to investigate the association between thyroid 
dysfunction and risk of developing gestational diabetes mellitus. 
 
(Das Bishnu Prasad et al., 2015) reported that, the risk of developing gestational diabetes 
increases with thyrotropin level.  Similar findings were reflected in the present study where, 
the incidence of GDM was found to be increased in subclinical hypothyroid and overt 
hypothyroid groups when compared with Euthyroid group (17.94% vs. 11%), (19.23 vs. 
11%).Interesting finding was, overt hypothyroid patients with GDM had higher levels of 
mean serum TSH in their early pregnancy when compared with non GDM patients within the 
same group (24.6 mU/liter vs. 11.18mU/liter).The proposed reason for the above findings is 
as follows, thyroid hormones play an important role in glucose metabolism. Triiodothyronine 
(T3) is the biologically active hormone that is primarily responsible for glucose metabolic 
activity(Pisarev et al.,2010) and 80% of circulating T3 is converted peripherally via 
deiodinase activity and the monodeiodination of T4 (Haddow et al.,2016).Studies have shown 
that several mechanisms are involved in the thyroid hormone-mediated regulation of glucose 
metabolism. This can be explained by the following: a) Reduce the half-life of insulin, 
accelerate the rate at which insulin is degraded, and increase the release of the inactive 
precursors of insulin; b) Promote hepatic glucose output by increasing the expression of 
glucose transporter 2 (GLUT2) in liver cell membranes and c) Activate β -adrenergic 
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receptors via CAMP, which increases the sensitivity of catecholamines, powerful hormones 
that accelerate glycogenolysis (Das et al., 1984).  
 
Studies have also shown that many of the pathways between the hypothalamic- pituitary axis 
and the T3 receptor in thyroid cells are abnormal in patients with diabetes (Yang et al., 2016). 
Pregnancies complicated with thyroid disorders especially, in hypothyroidism there is an 
increased chance of impaired glucose tolerance (Das Bishnu Prasad et al., 2015). Similar 
results were obtained in the present study where, oral glucose tolerant test (OGTT) mean 
values of GDM patients were significantly high in overt hypothyroid patients (169.2mg/dl) 
when compared with Euthyroid patients (144.8mg/dl). The proposed reason for the above 
findings is that patients with either hypothyroidism or subclinical hypothyroidism can exhibit 
insulin resistance. In vivo and in vitro studies have shown that this resistance may be caused 
by a reduced need for insulin or glucose utilization in peripheral tissues that have been 
damaged by insulin (Maratou et al., 2009). 
 
In the present study39.75%of study population were in the age group <25yrs out of which 
12.34% had developed GDM. 38.2% of the study population were between the age group 25 
to 29 out of which15.38% had developed GDM.18.1% of the study population were between 
the age group 30 to 34 out of which 16.21%developed GDM.3.92% of the study population 
were of the age ≥35 out of which 37.5%developed GDM. We found that, the incidence of 
GDM increased with increase in maternal age, our findings were in agreement with the 
previous studies who (Khalil et al., 2013) reported that incidence of GDM increases with 
maternal age reaching a plateau at around 40 years.  
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The reason for the above findings could be explained by the: i) association between aging and 
progressive vascular endothelial damage, ii) decreased insulin sensitivity with age and in 
individuals with impaired glucose tolerance (Fulop et al., 2003), iii) pancreatic ß cell function 
falls with age (Szoke et al., 2008). 
 
(Yang et al., 2016) reported that the incidence rate of GDM has gradually increased as pre 
pregnancy BMI has increased.  Similar results were obtained in the present study where 
5.39% of the study population who were underweight had 9.09% incidence of GDM. 36.9% 
of the study population who were normal weight had 12% incidence of GDM.40.19%of the 
study population who were overweight had 17.07% incidence of GDM.17.64%of the study 
population who were obese had 16.66% incidence of GDM.  The proposed reasons for 
increased GDM with increased pre pregnancy BMI are, in over weight and obese women 
insulin resistance is increased. The combination of obesity and insulin resistance increases the 
long-term risk of these individuals developing metabolic dysregulation in pregnancy, i.e. 
gestational diabetes (Catalano et al., 2010). 
Endocrine, inflammatory and neuronal pathways link obesity to insulin resistance. 
a) The obesity-associated increase in Fatty acids (FAs) can trigger insulin resistance through 
intracellular metabolites that activate protein kinase C (PKC), leading to the activation of 
serine/threonine kinases that inhibit insulin signaling.  b) Obesity-associated changes in 
secretion of adipokines that modulate insulin signaling. c) Obesity-associated inflammatory 
factors. Obesity is characterized by an increase in the accumulation of adipose tissue 
macrophages (ATMs), which increase the adipose tissue production of inflammatory 
cytokines that inhibit insulin signaling. d) Endocrine and inflammatory mediators converging 
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on serine/threonine kinases that inhibit insulin signaling.  e) Obesity-associated activation of 
NF-κB heightens inflammatory responses that exacerbate insulin resistance. f) suppressor of 
cytokine signaling (SOCS) family proteins, induced by adipokines, induce insulin resistance 
either by interfering with IRS-1 and IRS-2 tyrosine phosphorylation or by targeting IRS-1 and 
IRS-2 for proteosomal degradation. g) FAs also trigger insulin resistance by direct activation 
of TLR4 (toll like receptor) and the innate immune response. h) Obesity-related alteration in 
the central response to hormonal and nutrient signals alters peripheral insulin sensitivity 
(Qatanani et al., 2007). 
 
From the study results obtained, we found that, incidence of GDM increased with family 
history of diabetes,  history of thyroid, history of GDM when compared with  those patients 
without family history of diabetes, history of thyroid, history of GDM (17.6% vs 13.7%), 
(18.1% vs 14.2%) & (25% vs 14.2%) respectively.   The obtained results are not statistically 
significant, the reason might be a small sample size. 
 
In the present study we observed that, incidence of GDM was higher in patients with history 
of PCOD than those without history of PCOD (41.6% vs. 13.4%, p =0.037). The observed 
results are in consistent with the earlier reports (Jun et al., 2013) which states that Women 
with PCOD are at increased risk for developing GDM. Mechanisms that might explain an 
increased risk of GDM with history of PCOD are related to Insulin resistance which is 
believed to play an intrinsic role in the pathogenesis of PCOD (Dunaif et al., 1995) reported 
that, increased insulin receptor serine phosphorylation decreases its protein tyrosine kinase 
activity resulting in the post-binding defect in insulin action which is characteristic of PCOD. 
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Incidence of GDM was higher in patients with history of infertility than those without history 
of infertility (40.6% vs. 13.4%, p = 0.003). The observed results are in consistent with the 
earlier reports (Tobias et al., 2013) which suggested that infertility is associated with an 
increased risk of developing gestational diabetes mellitus. (Holst et al., 2016) mechanisms 
that might explain an increased risk of GDM after fertility problems are probably related to 
the underlying cause of infertility, the procedures involved in the treatment of infertility, or 
both (Ashrafi et al.,2014). Regarding the underlying fertility problems, it has been suggested 
that the association with risk of GDM is primarily attributable to PCOD. PCOD has been 
shown to increase the risk of GDM, possibly owing to a high prevalence of insulin resistance 
in these women (Boomsma et al., 2006).  Regarding the mechanisms associated with fertility 
treatment, researchers have argued that the hormonal environment induced during ART or 
ovulation induction may explain or contribute to the development of GDM (Maman et al., 
1998). For instance, the hormone progesterone, which is commonly used in fertility treatment 
(for luteal-phase support) has been suggested to have a diabetogenic effect in pregnancy, 
possibly by increasing insulin resistance in skeletal muscle and adipose tissue. Thus, it is 
biologically plausible that factors related to both the underlying fertility problem and fertility 
treatment increase the risk of GDM. 
 
(Stohl et al., 2013) reported that women with hypothyroidism had more incidence of GDM 
when compared to women with hyperthyroidism.  These findings are in contrast to the study 
by (Sahu et al., 2009) who demonstrated an association between hyperthyroidism and the 
development of GDM.  In the present study we could not enroll patients with hyperthyroidism 
as its prevalence is very less. 
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8. SUMMARY AND CONCLUSION 
 
In our present study we investigated the association between thyroid dysfunction and 
increased risk of developing gestational diabetes mellitus and assessed the other risk factors 
for developing gestational diabetes mellitus.  
 We found that, incidence of GDM is high in overt hypothyroid groups when compared 
with other groups. 
 Oral glucose tolerant test (OGTT) mean values of GDM patients were significantly 
high in overt hypothyroid patients when compared with Euthyroid patients. 
 Interesting finding was that, overt hypothyroid patients with GDM had significantly 
high mean serum TSH values in their early pregnancy when compared to overt 
hypothyroid patients without GDM thereby indicating the association between thyroid 
dysfunction in pregnancy and gestational diabetes mellitus. 
  Incidence of GDM increased with increase in age, BMI, family history of diabetes, 
history of GDM, history of thyroid but dint reach the statistical significance  
 Patients with history of PCOD and history of infertility had significantly higher 
incidence of GDM. 
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CONCLUSION 
 
The present study can be concluded that, thyroid dysfunction especially overt hypothyroidism 
is associated with increased risk of developing gestational diabetes mellitus. History of PCOD 
and history of infertility are the notable risk factors for developing GDM. 
 It is prudent to identify women with thyroid dysfunction at the earliest in order to detect 
gestational diabetes mellitus with least delay and treat with vigilance. However, a long term 
study covering a wide spectrum of patients is likely to provide a better knowledge in 
understanding the relationship between thyroid dysfunction and increased risk of developing 
gestational diabetes. 
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 FUTURE OUTLOOK 
 
This study can be continued in future by following up the women with Gestational diabetes 
mellitus to find out the Obstetric outcomes such as Delivery method and likelihood of 
developing DM type 2  
Post-delivery neonatal outcomes such as Shoulder dystocia/ birth trauma, Macrosomia, Birth 
defects, Hyperbilirubinemia, Hypoglycemia 
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